COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: TED  ROSS
Organization: UNIVERSITY OF GEORGIA
Fiscal Year: 2020
Award: $969,746
Funding agency: National Institute of Allergy and Infectious Diseases

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”).

Terms: <2019 novel coronavirus><2019-nCoV><Animal Model><Animal Models and Related Studies><Animals><COVID><CoV disease><Contracting Opportunities><Contractor><Contracts><Coronaviridae><Coronavirus><Elderly><History><Human><Immune><Immune response><Immunes><Immunity><Immunological response><Individual><Influenza Vaccines><Modern Man><Mucosa><Mucosal Tissue><Mucous Membrane><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Obesity><Recording of previous events><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe acute respiratory syndrome coronavirus 2><United States National Institutes of Health><Vaccinated><Vaccines><Wuhan coronavirus><adiposity><advanced age><anti-flu><anti-influenza><antiflu><corona virus><corona virus disease><coronavirus disease><corpulence><corpulency><corpulentia><design><designing><develop a vaccine><development of a vaccine><elders><flu vaccine><flu virus vaccine><geriatric><high risk><high risk group><high risk population><host response><immunogenicity><immunoresponse><influenza virus vaccine><innovate><innovation><innovative><late life><later life><model of animal><model organism><new vaccines><next generation><next generation vaccines><novel vaccines><obese><obese people><obese person><obese population><older adult><older person><pregnant><programs><response><seasonal flu><seasonal influenza><senior citizen><standard of care><universal flu vaccine><universal influenza vaccine><universal vaccine><vaccine against flu><vaccine against influenza><vaccine development><vaccine formulation>